Free Trial
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

Alkermes logo
$35.36 -0.14 (-0.39%)
As of 01:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Alkermes Stock (NASDAQ:ALKS)

Key Stats

Today's Range
$35.16
$35.79
50-Day Range
$28.08
$36.00
52-Week Range
$22.90
$36.45
Volume
251,746 shs
Average Volume
1.69 million shs
Market Capitalization
$5.75 billion
P/E Ratio
16.22
Dividend Yield
N/A
Price Target
$38.36
Consensus Rating
Moderate Buy

Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

ALKS MarketRank™: 

Alkermes scored higher than 75% of companies evaluated by MarketBeat, and ranked 270th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alkermes has only been the subject of 3 research reports in the past 90 days.

  • Read more about Alkermes' stock forecast and price target.
  • Earnings Growth

    Earnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alkermes is 16.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.35.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alkermes is 16.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.93.

  • Price to Earnings Growth Ratio

    Alkermes has a PEG Ratio of 2.23. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Alkermes has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alkermes' valuation and earnings.
  • Percentage of Shares Shorted

    6.83% of the float of Alkermes has been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Alkermes has recently decreased by 4.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Alkermes does not currently pay a dividend.

  • Dividend Growth

    Alkermes does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.83% of the float of Alkermes has been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Alkermes has recently decreased by 4.84%, indicating that investor sentiment is improving.
  • News Sentiment

    Alkermes has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Alkermes this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,854,725.00 in company stock.

  • Percentage Held by Insiders

    Only 4.89% of the stock of Alkermes is held by insiders.

  • Percentage Held by Institutions

    95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alkermes' insider trading history.
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Stock News Headlines

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Alkermes (ALKS) Projected to Post Earnings on Thursday
HC Wainwright Predicts Alkermes' Q1 Earnings (NASDAQ:ALKS)
Alkermes' (ALKS) Neutral Rating Reiterated at HC Wainwright
See More Headlines

ALKS Stock Analysis - Frequently Asked Questions

Alkermes' stock was trading at $28.76 at the beginning of 2025. Since then, ALKS stock has increased by 22.5% and is now trading at $35.2410.
View the best growth stocks for 2025 here
.

Alkermes plc (NASDAQ:ALKS) issued its earnings results on Wednesday, February, 12th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a trailing twelve-month return on equity of 30.80% and a net margin of 23.57%.

Alkermes' Board of Directors authorized a stock buyback plan on Thursday, February 15th 2024, which authorizes the company to buy back $400,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 8.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's management believes its stock is undervalued.

The following companies are subsidiaries of Alkermes: Rodin Therapeutics.

Top institutional shareholders of Alkermes include Vanguard Group Inc. (11.43%), Price T Rowe Associates Inc. MD (7.58%), RTW Investments LP (4.67%) and Wellington Management Group LLP (4.33%). Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski.
View institutional ownership trends
.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
2/12/2025
Today
2/21/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
1,800
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$38.36
High Stock Price Target
$50.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+9.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$367.07 million
Pretax Margin
28.49%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$2.60 per share
Book Value
$9.01 per share

Miscellaneous

Free Float
154,662,000
Market Cap
$5.72 billion
Optionable
Optionable
Beta
0.49

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:ALKS) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners